


<b>Author Year; Country Score Research Design Total Sample Size</b>	<b>Methods</b>	<b>Outcome</b>
<p><a href="#">Bauman et al. 2005a</a>; USA PEDro=10 RCT Level 1 N=14</p>	<p><b>Population:</b> 14 participants (8 men, 3 women); age: 35 ± 12 years (range: 21–61); motor complete para (n=6) or tetraplegia (n=5); TPI: 44 ± 18 days (range: 22–65). AIS A.</p> <p><b>Treatment:</b> Pamidronate for 12 months. Participants randomized to <b>1.</b> 60mg intravenous (n=6) or <b>2.</b> Placebo (n=5)</p> <p><b>Outcome measures:</b> BMD by DXA, bone turnover markers at baseline, 1, 2, 3, 6, 9, 12-months post-SCI.</p> <p><b>Effect Sizes:</b> Forest plot of standardized mean differences (SMD ± 95%CI) as calculated from pre- to post-intervention data and pre-intervention to retention/follow-up data</p> <p>12 &amp; 24 months post-baseline data used as post-treatment &amp; retention data, respectively</p>	<ol style="list-style-type: none"> <li>1. There was no significant between-group difference in BMD decline at 1 year.</li> <li>2. The treatment group had significantly lower 24-hr urinary calcium at 1 month vs. placebo group (P&lt;0.05) and there were no significant changes in markers of bone formation over the 12-month study.</li> </ol>
<p><a href="#">Minaire et al.</a></p>	<p><b>Population:</b> 17 men and 4 women;</p>	<ol style="list-style-type: none"> <li>1. No reported adverse</li> </ol>

<b>Author Year; Country Score Research Design Total Sample Size</b>	<b>Methods</b>	<b>Outcome</b>
<p><a href="#">1981</a> France PEDro=10 RCT Level 1 N=21</p>	<p>age: 29 years (range: 15-54); traumatic complete paraplegia; T1 - T12; TPI: 7.6 days (range: 5-29).  <b>Treatment:</b> Clodronate for 3.5 months. Participants randomized to <b>1.</b> 400mg per day (n=7); <b>2.</b> 1,600 per day (n=7); or <b>3.</b> Placebo (n=7).  <b>Outcome measures:</b> BMD by DPA, histomorphometry</p>	<p>effects on bone mineralization with intervention.</p> <ol style="list-style-type: none"> <li>2. Increase in serum and urine markers in the Placebo group (indicative of increased bone turnover).</li> <li>3. Effective for acute prevention of declining bone mass and maintenance of BMC of the femur and tibia in the treatment groups.</li> </ol>
	<p><b>Effect Sizes:</b> Forest plot of standardized mean differences (SMD ± 95%CI) as calculated from pre- to post-intervention data and pre-intervention to retention/follow-up data</p>	

<b>Author Year; Country Score Research Design Total Sample Size</b>	<b>Methods</b>	<b>Outcome</b>																																
	<p style="text-align: center;"><b>Minaire et al. 1981; Disodium Dichloromethylene Diphosphate 400mg/day</b></p> <p>BMC @ Lower End of Tibia (Pre-&gt;Post)</p> <p>Osteoclast Density in Tb. (Pre-&gt;Post)</p> <p>Periosteocytic Lacunae Size (Pre-&gt;Post)</p> <p>Serum Alkaline Phosphatase (Pre-&gt;Post)</p> <p>Serum Phosphate (Pre-&gt;Post)</p> <p>Thickness Idx. of Osteoid Seams (Pre-&gt;Post)</p> <p>Total Bone Density (Pre-&gt;Post)</p> <p>Total Resorption Surface (Pre-&gt;Post)</p> <p>Tb. Volume (Image Analyzer) (Pre-&gt;Post)</p> <p>Tb. Volume (Manual Method) (Pre-&gt;Post)</p> <p>Trabecular Osteoid Surfaces (Pre-&gt;Post)</p> <p>Trabecular Osteoid Volume (Pre-&gt;Post)</p> <p>BMC @ Lower End of Tibia (Pre-&gt;Ret)</p> <p>Serum Alkaline Phosphatase (Pre-&gt;Ret)</p> <p>Serum Phosphate (Pre-&gt;Ret)</p> <p>Tb. = trabecular bone</p>	<table border="1"> <caption>Forest Plot Data</caption> <thead> <tr> <th>Outcome</th> <th>SMD (95% C.I.)</th> </tr> </thead> <tbody> <tr> <td>BMC @ Lower End of Tibia (Pre-&gt;Post)</td> <td>0.49 (-0.58, 1.55)</td> </tr> <tr> <td>Osteoclast Density in Tb. (Pre-&gt;Post)</td> <td>0.57 (-0.50, 1.65)</td> </tr> <tr> <td>Periosteocytic Lacunae Size (Pre-&gt;Post)</td> <td>0.24 (-0.81, 1.29)</td> </tr> <tr> <td>Serum Alkaline Phosphatase (Pre-&gt;Post)</td> <td>1.96 (0.61, 3.32)</td> </tr> <tr> <td>Serum Phosphate (Pre-&gt;Post)</td> <td>0.79 (-0.31, 1.89)</td> </tr> <tr> <td>Thickness Idx. of Osteoid Seams (Pre-&gt;Post)</td> <td>1.71 (0.42, 2.99)</td> </tr> <tr> <td>Total Bone Density (Pre-&gt;Post)</td> <td>-0.18 (-1.23, 0.87)</td> </tr> <tr> <td>Total Resorption Surface (Pre-&gt;Post)</td> <td>0.99 (-0.14, 2.12)</td> </tr> <tr> <td>Tb. Volume (Image Analyzer) (Pre-&gt;Post)</td> <td>-0.13 (-1.18, 0.92)</td> </tr> <tr> <td>Tb. Volume (Manual Method) (Pre-&gt;Post)</td> <td>-0.13 (-1.18, 0.92)</td> </tr> <tr> <td>Trabecular Osteoid Surfaces (Pre-&gt;Post)</td> <td>0.28 (-0.78, 1.33)</td> </tr> <tr> <td>Trabecular Osteoid Volume (Pre-&gt;Post)</td> <td>-0.35 (-1.41, 0.71)</td> </tr> <tr> <td>BMC @ Lower End of Tibia (Pre-&gt;Ret)</td> <td>1.94 (0.59, 3.29)</td> </tr> <tr> <td>Serum Alkaline Phosphatase (Pre-&gt;Ret)</td> <td>1.23 (0.05, 2.40)</td> </tr> <tr> <td>Serum Phosphate (Pre-&gt;Ret)</td> <td>-0.16 (-1.21, 0.89)</td> </tr> </tbody> </table>	Outcome	SMD (95% C.I.)	BMC @ Lower End of Tibia (Pre->Post)	0.49 (-0.58, 1.55)	Osteoclast Density in Tb. (Pre->Post)	0.57 (-0.50, 1.65)	Periosteocytic Lacunae Size (Pre->Post)	0.24 (-0.81, 1.29)	Serum Alkaline Phosphatase (Pre->Post)	1.96 (0.61, 3.32)	Serum Phosphate (Pre->Post)	0.79 (-0.31, 1.89)	Thickness Idx. of Osteoid Seams (Pre->Post)	1.71 (0.42, 2.99)	Total Bone Density (Pre->Post)	-0.18 (-1.23, 0.87)	Total Resorption Surface (Pre->Post)	0.99 (-0.14, 2.12)	Tb. Volume (Image Analyzer) (Pre->Post)	-0.13 (-1.18, 0.92)	Tb. Volume (Manual Method) (Pre->Post)	-0.13 (-1.18, 0.92)	Trabecular Osteoid Surfaces (Pre->Post)	0.28 (-0.78, 1.33)	Trabecular Osteoid Volume (Pre->Post)	-0.35 (-1.41, 0.71)	BMC @ Lower End of Tibia (Pre->Ret)	1.94 (0.59, 3.29)	Serum Alkaline Phosphatase (Pre->Ret)	1.23 (0.05, 2.40)	Serum Phosphate (Pre->Ret)	-0.16 (-1.21, 0.89)
Outcome	SMD (95% C.I.)																																	
BMC @ Lower End of Tibia (Pre->Post)	0.49 (-0.58, 1.55)																																	
Osteoclast Density in Tb. (Pre->Post)	0.57 (-0.50, 1.65)																																	
Periosteocytic Lacunae Size (Pre->Post)	0.24 (-0.81, 1.29)																																	
Serum Alkaline Phosphatase (Pre->Post)	1.96 (0.61, 3.32)																																	
Serum Phosphate (Pre->Post)	0.79 (-0.31, 1.89)																																	
Thickness Idx. of Osteoid Seams (Pre->Post)	1.71 (0.42, 2.99)																																	
Total Bone Density (Pre->Post)	-0.18 (-1.23, 0.87)																																	
Total Resorption Surface (Pre->Post)	0.99 (-0.14, 2.12)																																	
Tb. Volume (Image Analyzer) (Pre->Post)	-0.13 (-1.18, 0.92)																																	
Tb. Volume (Manual Method) (Pre->Post)	-0.13 (-1.18, 0.92)																																	
Trabecular Osteoid Surfaces (Pre->Post)	0.28 (-0.78, 1.33)																																	
Trabecular Osteoid Volume (Pre->Post)	-0.35 (-1.41, 0.71)																																	
BMC @ Lower End of Tibia (Pre->Ret)	1.94 (0.59, 3.29)																																	
Serum Alkaline Phosphatase (Pre->Ret)	1.23 (0.05, 2.40)																																	
Serum Phosphate (Pre->Ret)	-0.16 (-1.21, 0.89)																																	

<b>Author Year; Country Score Research Design Total Sample Size</b>	<b>Methods</b>	<b>Outcome</b>
---	----------------	----------------



<p><a href="#">Chappard et al. 1995</a>; France PEDro=9 RCT Level 1 N=20</p>	<p><b>Population:</b> 20 participants (14 men, 6 women), age: 28.0 + 6.4 years; traumatic injuries between C5-T12.</p> <p><b>Treatment:</b> Tiludronate for 3 months. Participants randomized to <b>1.</b> 400 mg/day (n=7); <b>2.</b> 200 mg/day (n=7); or <b>3.</b> Placebo (n=6).</p> <p><b>Outcome measures:</b> histomorphometry.</p>	<ol style="list-style-type: none"> <li>There was an increase in total bone volume in the treatment group 1(400mg/day) vs. treatment group 2 (200mg/day) and placebo groups.</li> <li>Increased bone resorption indicators in the placebo group vs. the treatment groups.</li> </ol>
--	--	---

**Effect Sizes:** Forest plot of standardized mean differences (SMD ± 95%CI) as calculated from pre- and post-intervention data

<b>Author Year; Country Score Research Design Total Sample Size</b>	<b>Methods</b>	<b>Outcome</b>
	<p style="text-align: center;"><b>Chappard et al. 1995; Titudronate 200 mg/day</b></p> <p style="text-align: center;"><b>Chappard et al. 1995; Titudronate 400 mg/day</b></p>	
<p><a href="#">Schnitzer et al. 2016</a>; USA PEDro=8 RCT Level 1 N=16</p>	<p><b>Population:</b> 16 participants (15 men, 1 women) with acute SCI; AIS-A/B, or AIS-C; and non-weight-bearing; age: 38.6 ± 16.2 years; 8 cervical, 8 thoracic; TPI: Placebo = 95.3 ± 50.0 days, Zoledronic acid: 35.1 ± 15.4 days.</p> <p><b>Treatment:</b> Infusion of zoledronic acid (5 mg) or placebo (dilutant</p>	<p>1. Significant between-group difference at 6 months post-treatment in change of (mean±SD, zoledronic acid vs. placebo):</p> <p>Lumbar spine BMD: +2.4±1.8% vs. -2.5±2.2%</p> <p>Left total hip BMD: -3.7±1.0% vs. -12.3±6.9%</p>


<b>Author Year; Country Score Research Design Total Sample Size</b>	<b>Methods</b>	<b>Outcome</b>
	<p>only)</p> <p><b>Outcome measures:</b> BMD by DXA, bone turnover markers at baseline, 3, 6, 12-months post-treatment.</p>	<p>Right total hip BMD: -2.2±3.4% vs. -8.6±3.5%</p> <p>Left femoral neck BMD: -1.1±3.5% vs. -11.1±7.4%</p> <p>Right femoral neck BMD: -5.1±6.5% vs. -20.0±6.4%</p> <ol style="list-style-type: none"> <li>2. Zoledronic acid group observed decreased BMD for left &amp; right total hip and femoral neck but observed increased BMD for lumbar spine over 18-24 months post-treatment</li> <li>3. Elevated levels of serum CTX and P1NP at baseline, and are reduced at 3 months in both zoledronic acid and placebo groups</li> <li>4. Delayed zoledronic acid infusion in those with &gt;10% BMD loss after 6 months of placebo resulted in stabilization in total hip, left femoral neck, and lumbar spine; however, BMD of left distal femur continued to decline</li> <li>5. No adverse effects other than temperature elevations (n=3)</li> </ol>
	<p><b>Effect Sizes:</b> Forest plot of standardized mean differences (SMD ± 95%CI) as calculated from pre- and post-intervention data</p>	


<b>Author Year; Country Score Research Design Total Sample Size</b>	<b>Methods</b>	<b>Outcome</b>																		
	<p style="text-align: center;"><b>Schnitzer et al. 2016; Zoledronic Acid</b></p> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th>BMD Site</th> <th>SMD (95% C.I.)</th> </tr> </thead> <tbody> <tr> <td>BMD Lumbar Spine</td> <td>2.25 (0.67, 3.83)</td> </tr> <tr> <td>BMD Left Hip</td> <td>1.61 (0.23, 2.99)</td> </tr> <tr> <td>BMD Right Hip</td> <td>1.71 (0.31, 3.12)</td> </tr> <tr> <td>BMD Left Femoral Neck</td> <td>1.59 (0.22, 2.97)</td> </tr> <tr> <td>BMD Right Femoral Neck</td> <td>2.13 (0.59, 3.67)</td> </tr> <tr> <td>BMD Distal Femoral Epiphysis</td> <td>0.11 (-1.02, 1.25)</td> </tr> <tr> <td>BMD Distal Femoral Metaphysis</td> <td>0.48 (-0.68, 1.64)</td> </tr> <tr> <td>BMD Proximal Tibia</td> <td>1.26 (-0.03, 2.55)</td> </tr> </tbody> </table>	BMD Site	SMD (95% C.I.)	BMD Lumbar Spine	2.25 (0.67, 3.83)	BMD Left Hip	1.61 (0.23, 2.99)	BMD Right Hip	1.71 (0.31, 3.12)	BMD Left Femoral Neck	1.59 (0.22, 2.97)	BMD Right Femoral Neck	2.13 (0.59, 3.67)	BMD Distal Femoral Epiphysis	0.11 (-1.02, 1.25)	BMD Distal Femoral Metaphysis	0.48 (-0.68, 1.64)	BMD Proximal Tibia	1.26 (-0.03, 2.55)	
BMD Site	SMD (95% C.I.)																			
BMD Lumbar Spine	2.25 (0.67, 3.83)																			
BMD Left Hip	1.61 (0.23, 2.99)																			
BMD Right Hip	1.71 (0.31, 3.12)																			
BMD Left Femoral Neck	1.59 (0.22, 2.97)																			
BMD Right Femoral Neck	2.13 (0.59, 3.67)																			
BMD Distal Femoral Epiphysis	0.11 (-1.02, 1.25)																			
BMD Distal Femoral Metaphysis	0.48 (-0.68, 1.64)																			
BMD Proximal Tibia	1.26 (-0.03, 2.55)																			
<p><a href="#">Pearson et al. 1997</a> Canada PEDro=8 RCT Level 1 N=13</p>	<p><b>Population:</b> 12 men and 1 woman; age: 22-57 years; injuries between C5-T12; AIS: A or D. <b>Treatment:</b> Etidronate for 30 weeks. Participants randomized to 1. 800mg daily (n=6; 5 men 1 woman; mean age: 35.6 years) or 2. Conventional rehab and calcium 1000mg/day (n=7; 7 men; mean age: 33.6 years). <b>Outcome measures:</b> DXA and adverse event rate.</p>	<ol style="list-style-type: none"> <li>BMD loss at the distal femur was 26% and 22% at the proximal tibia. The rate of decline in BMD was greatest amongst the AIS A individuals. BMD of lower extremity for the Etidronate-treated AIS D individuals was preserved.</li> <li>Oral Etidronate was safe and well-tolerated by participants.</li> </ol>																		
<p><a href="#">Gilchrist et al. 2007</a> New Zealand PEDro=7 RCT Level 1 N=31</p>	<p><b>Population:</b> 31 participants (22 men, 9 women) age: 17-55 years; 10 AIS A, 1 AIS B, and 3 AIS C. <b>Treatment:</b> Alendronate (oral) for 12 months within 10 days of acute injury. Participants randomized to 1. 70 mg once weekly (n=15; 10 men and 5 women); or 2. Placebo (n=16;</p>	<ol style="list-style-type: none"> <li>BMD at the femoral neck was maintained in the treatment group, and there was less BMD loss at other hip sites compared with the placebo group.</li> <li>BMD at the hip in the Placebo group declined</li> </ol>																		

<b>Author Year; Country Score Research Design Total Sample Size</b>	<b>Methods</b>	<b>Outcome</b>
	<p>12 men and 4 women).</p> <p><b>Outcome Measures:</b> BMD and body composition by DXA, ultrasound, bone turnover markers.</p>	<p>steadily over the 18 months follow-up.</p> <p>3. At 12 months, there was a 5.3% difference in total body BMD and a 17.6% difference in the percent change in total hip BMD between the two groups.</p> <p>4. Alendronate compared with placebo-induced reductions in urinary calcium excretion and serum CTX at 3 months only.</p>
	<p><b>Effect Sizes:</b> Forest plot of standardized mean differences (SMD <math>\pm</math> 95%CI) as calculated from pre- to post-intervention data and pre-intervention to retention/follow-up data</p>	



<b>Author Year; Country Score Research Design Total Sample Size</b>	<b>Methods</b>	<b>Outcome</b>																																		
	<p style="text-align: center;">Gilchrist et al. 2007; Oral Alendronate 70 mg/wk</p> <p>BMD Lumbar Spine (Pre-&gt;Post)</p> <p>BMD Hip (Pre-&gt;Post)</p> <p>BMD Femoral Neck (Pre-&gt;Post)</p> <p>BMD Trochanter (Pre-&gt;Post)</p> <p>BMD Femoral Shaft (Pre-&gt;Post)</p> <p>BMD Total Body (Pre-&gt;Post)</p> <p>BMD Total Arms (Pre-&gt;Post)</p> <p>BMD Total Legs (Pre-&gt;Post)</p> <p>BMD Lumbar Spine (Pre-&gt;Ret)</p> <p>BMD Hip (Pre-&gt;Ret)</p> <p>BMD Femoral Neck (Pre-&gt;Ret)</p> <p>BMD Trochanter (Pre-&gt;Ret)</p> <p>BMD Femoral Shaft (Pre-&gt;Ret)</p> <p>BMD Total Body (Pre-&gt;Ret)</p> <p>BMD Total Arms (Pre-&gt;Ret)</p> <p>BMD Total Legs (Pre-&gt;Ret)</p>	<table border="1"> <caption>BMD Outcomes (SMD (95% C.I.))</caption> <thead> <tr> <th>Outcome</th> <th>SMD (95% C.I.)</th> </tr> </thead> <tbody> <tr><td>BMD Lumbar Spine (Pre-&gt;Post)</td><td>0.30 (-0.49, 1.09)</td></tr> <tr><td>BMD Hip (Pre-&gt;Post)</td><td>0.28 (-0.51, 1.07)</td></tr> <tr><td>BMD Femoral Neck (Pre-&gt;Post)</td><td>0.85 (0.03, 1.68)</td></tr> <tr><td>BMD Trochanter (Pre-&gt;Post)</td><td>1.05 (0.21, 1.90)</td></tr> <tr><td>BMD Femoral Shaft (Pre-&gt;Post)</td><td>0.80 (-0.03, 1.62)</td></tr> <tr><td>BMD Total Body (Pre-&gt;Post)</td><td>0.46 (-0.34, 1.26)</td></tr> <tr><td>BMD Total Arms (Pre-&gt;Post)</td><td>0.36 (-0.43, 1.15)</td></tr> <tr><td>BMD Total Legs (Pre-&gt;Post)</td><td>0.52 (-0.28, 1.32)</td></tr> <tr><td>BMD Lumbar Spine (Pre-&gt;Ret)</td><td>0.39 (-0.41, 1.18)</td></tr> <tr><td>BMD Hip (Pre-&gt;Ret)</td><td>0.27 (-0.52, 1.06)</td></tr> <tr><td>BMD Femoral Neck (Pre-&gt;Ret)</td><td>0.78 (-0.04, 1.60)</td></tr> <tr><td>BMD Trochanter (Pre-&gt;Ret)</td><td>0.91 (0.08, 1.75)</td></tr> <tr><td>BMD Femoral Shaft (Pre-&gt;Ret)</td><td>0.83 (0.00, 1.65)</td></tr> <tr><td>BMD Total Body (Pre-&gt;Ret)</td><td>0.50 (-0.30, 1.30)</td></tr> <tr><td>BMD Total Arms (Pre-&gt;Ret)</td><td>0.76 (-0.06, 1.58)</td></tr> <tr><td>BMD Total Legs (Pre-&gt;Ret)</td><td>0.56 (-0.24, 1.37)</td></tr> </tbody> </table> <p style="text-align: center;">-2   -1.5   -1   -0.5   0   0.5   1   1.5   2</p> <p style="text-align: center;">Favours Control      SMD (95% C.I.)      Favours Treatment</p> <p>SD calculated from Standard Error of the Mean (SEM)</p>	Outcome	SMD (95% C.I.)	BMD Lumbar Spine (Pre->Post)	0.30 (-0.49, 1.09)	BMD Hip (Pre->Post)	0.28 (-0.51, 1.07)	BMD Femoral Neck (Pre->Post)	0.85 (0.03, 1.68)	BMD Trochanter (Pre->Post)	1.05 (0.21, 1.90)	BMD Femoral Shaft (Pre->Post)	0.80 (-0.03, 1.62)	BMD Total Body (Pre->Post)	0.46 (-0.34, 1.26)	BMD Total Arms (Pre->Post)	0.36 (-0.43, 1.15)	BMD Total Legs (Pre->Post)	0.52 (-0.28, 1.32)	BMD Lumbar Spine (Pre->Ret)	0.39 (-0.41, 1.18)	BMD Hip (Pre->Ret)	0.27 (-0.52, 1.06)	BMD Femoral Neck (Pre->Ret)	0.78 (-0.04, 1.60)	BMD Trochanter (Pre->Ret)	0.91 (0.08, 1.75)	BMD Femoral Shaft (Pre->Ret)	0.83 (0.00, 1.65)	BMD Total Body (Pre->Ret)	0.50 (-0.30, 1.30)	BMD Total Arms (Pre->Ret)	0.76 (-0.06, 1.58)	BMD Total Legs (Pre->Ret)	0.56 (-0.24, 1.37)
Outcome	SMD (95% C.I.)																																			
BMD Lumbar Spine (Pre->Post)	0.30 (-0.49, 1.09)																																			
BMD Hip (Pre->Post)	0.28 (-0.51, 1.07)																																			
BMD Femoral Neck (Pre->Post)	0.85 (0.03, 1.68)																																			
BMD Trochanter (Pre->Post)	1.05 (0.21, 1.90)																																			
BMD Femoral Shaft (Pre->Post)	0.80 (-0.03, 1.62)																																			
BMD Total Body (Pre->Post)	0.46 (-0.34, 1.26)																																			
BMD Total Arms (Pre->Post)	0.36 (-0.43, 1.15)																																			
BMD Total Legs (Pre->Post)	0.52 (-0.28, 1.32)																																			
BMD Lumbar Spine (Pre->Ret)	0.39 (-0.41, 1.18)																																			
BMD Hip (Pre->Ret)	0.27 (-0.52, 1.06)																																			
BMD Femoral Neck (Pre->Ret)	0.78 (-0.04, 1.60)																																			
BMD Trochanter (Pre->Ret)	0.91 (0.08, 1.75)																																			
BMD Femoral Shaft (Pre->Ret)	0.83 (0.00, 1.65)																																			
BMD Total Body (Pre->Ret)	0.50 (-0.30, 1.30)																																			
BMD Total Arms (Pre->Ret)	0.76 (-0.06, 1.58)																																			
BMD Total Legs (Pre->Ret)	0.56 (-0.24, 1.37)																																			
<p><a href="#">Shapiro et al. 2007</a></p> <p>USA</p> <p>PEDro=7</p> <p>RCT</p> <p>Level 1</p> <p>N=18</p>	<p><b>Population:</b> 14 men and 4 women with traumatic SCI; age: 18-60 years (Placebo: 28.4 ± 9.4; Treatment: 30.1 ± 14.2); tetraplegia (n=5) or paraplegia (n=13); AIS A (n=14) or AIS B (n=4).</p> <p><b>Treatment:</b> Zoledronic acid. Participants randomized to 1. Single-dose intravenous solution either 4mg (n=4) or 5mg (n=4)</p>	<p>1. Treatment group: Six months after zoledronic acid, BMD, bone cross-sectional area, and sectional modulus increased at the hip and buckling ratio decreased consistently with improved bone outcomes. At 12 months, narrow-</p>																																		

<b>Author Year; Country Score Research Design Total Sample Size</b>	<b>Methods</b>	<b>Outcome</b>
	<p>(Total n=8), or 2. Placebo group received 50ml of normal saline over 15 minutes (n=10) Participants with low serum 25-hydroxyvitamin D received oral supplementation.  <b>Outcome Measures:</b> bone turnover markers, BMD by DXA</p>	<p>neck femur values declined, and intertrochanteric and femoral shaft BMD was maintained.  2. Placebo group: decrease in bone outcomes and an increase in buckling ratio at the hip at 6 and 12 months.</p>
<p><b>Effect Sizes:</b> Forest plot of standardized mean differences (SMD ± 95%CI) as calculated from pre- and post-intervention data</p> <p style="text-align: center;">Shapiro et al., 2007; Zoledronic Acid (4 or 5mg)</p>  <p style="text-align: center;">Urine NTx/Cr (0-12mo)</p> <p style="text-align: center;">-2    -1.5    -1    -0.5    0    0.5    1    1.5    2</p> <p style="text-align: center;">Favours Control                      SMD (95%CI.)                      Favours Treatment</p> <p style="text-align: center;">0.72 (-0.27,1.71)</p>		
<p><a href="#">Minaire et al. 1987</a>  France  PEDro=7  RCT  Level 1  N=21</p>	<p><b>Population:</b> 21 men and women; age: 15-54 years, complete paraplegia.  <b>Treatment:</b> Clodronate for 100 days. Participants randomized to <b>1.</b> 400mg per day (n=7); <b>2.</b> 1,600 per day (n=7); or <b>3.</b> Placebo (n=7).  <b>Outcome measures:</b> DXA, histomorphometry, bone turnover markers.</p>	<ol style="list-style-type: none"> <li>1. There was a greater increase in bone removal markers in Placebo group (48%), compared with treatment groups (17-27%).</li> <li>2. BMD was maintained in treatment groups with a ↓ in placebo group.</li> <li>3. Lower bone turnover markers in treatment groups.</li> </ol>
<p><a href="#">Bubbear et al. 2011</a>  UK  PEDro=6</p>	<p><b>Population:</b> 14 acute SCI participants (Control: 5 men, 2 women; mean age 27 ± 14.4;</p>	<ol style="list-style-type: none"> <li>1. Significant difference between control and treatment groups over 12 months at lumbar spine</li> </ol>

<b>Author Year; Country Score Research Design Total Sample Size</b>	<b>Methods</b>	<b>Outcome</b>																
<p>RCT Level 1 N = 14</p>	<p>Treatment: 4 men, 3 women; mean age <math>31.6 \pm 7.1</math>)  <b>Treatment:</b> 4 mg intravenous zoledronic acid (active treatment group) or standard nursing/medical care (control group)  <b>Outcome Measures:</b> BMD using DXA at baseline, 3, 6, 12 months for lumbar spine (L1-4) and hip (total, femoral neck, trochanter); Bone turnover markers (serum CTX and PINP) and urinary N-terminal telopeptide/creatinine ratio).</p>	<p>(<math>+0.8 \pm 4.9\%</math> vs. <math>+3.5 \pm 3.9\%</math>, <math>p = 0.033</math>), total hip (<math>-15.8 \pm 8.9\%</math> vs. <math>-3.4 \pm 3.0\%</math>, <math>p=0.005</math>), trochanter (<math>-17.9 \pm 9.4\%</math> vs. <math>-4.5 \pm 5.7\%</math>, <math>p=0.028</math>)</p> <ol style="list-style-type: none"> <li>No significant difference between groups with femoral neck BMD or with creatine markers.</li> <li>Bone turnover markers normalized within 6 weeks to 3 months in treatment group vs to up to 12 months in control group</li> <li>5 of 7 participants in zoledronic group had flu-like symptoms over 24 hours</li> </ol>																
<p><b>Effect Sizes:</b> Forest plot of standardized mean differences (SMD <math>\pm</math> 95%CI) as calculated from pre- and post-intervention data</p>  <table border="1" data-bbox="446 1365 1477 1806"> <caption>Bubbear et al. 2011; Zoledronic acid</caption> <thead> <tr> <th>Outcome</th> <th>SMD (95%CI)</th> </tr> </thead> <tbody> <tr> <td>BMD lumbar spine</td> <td>0.26 (-0.93, 1.46)</td> </tr> <tr> <td>BMD total hip</td> <td>0.04 (-1.14, 1.23)</td> </tr> <tr> <td>BMD femoral neck</td> <td>-0.44 (-1.65, 0.77)</td> </tr> <tr> <td>BMD trochanter</td> <td>0.03 (-1.16, 1.22)</td> </tr> <tr> <td>PINP</td> <td>0.33 (-0.87, 1.53)</td> </tr> <tr> <td>CTX</td> <td>0.57 (-0.65, 1.79)</td> </tr> <tr> <td>NTX/Cr</td> <td>-0.32 (-1.51, 0.88)</td> </tr> </tbody> </table>			Outcome	SMD (95%CI)	BMD lumbar spine	0.26 (-0.93, 1.46)	BMD total hip	0.04 (-1.14, 1.23)	BMD femoral neck	-0.44 (-1.65, 0.77)	BMD trochanter	0.03 (-1.16, 1.22)	PINP	0.33 (-0.87, 1.53)	CTX	0.57 (-0.65, 1.79)	NTX/Cr	-0.32 (-1.51, 0.88)
Outcome	SMD (95%CI)																	
BMD lumbar spine	0.26 (-0.93, 1.46)																	
BMD total hip	0.04 (-1.14, 1.23)																	
BMD femoral neck	-0.44 (-1.65, 0.77)																	
BMD trochanter	0.03 (-1.16, 1.22)																	
PINP	0.33 (-0.87, 1.53)																	
CTX	0.57 (-0.65, 1.79)																	
NTX/Cr	-0.32 (-1.51, 0.88)																	

<b>Author Year; Country Score Research Design Total Sample Size</b>	<b>Methods</b>	<b>Outcome</b>
<p><a href="#">Nance et al. 1999</a> Canada Prospective Controlled trial (nonrandom ized) Level 2 N=24</p>	<p><b>Population:</b> 22 men and 2 women, ages 25-57, injuries between C5-T12, AIS A-D. <b>Treatment:</b> Pamidronate for 6 months. Participants randomized to 30 mg intravenous every 4 weeks x 6 doses (total 180 mg/participant) [n=14; 30.8 ± 8.3 years (range 20 - 45)] or conventional rehab [n=10; 35.1 ± 10 years (range 25 - 57)]. <b>Outcome measures:</b> BMD by DXA, urine biochemical bone markers.</p>	<p>1. There was a lower % decline in BMD in treatment vs. control group. The mean overall BMD decline was 8.1% in the placebo group but only 2.7% in the treatment group (p=0.02). The average loss of BMD was 3.1% in the AIS D group and 7.7% in the AIS A group.</p>

\* All data expressed as mean±SD, unless expressed otherwise.